Magnolol depresses urotensin-ii-induced cell proliferation in rat cardiac fibroblasts

Clinical and Experimental Pharmacology and Physiology

Volumn 36, Issue 7, 2009, Pages 711-716

  Liou, Jer Young ^a   Chen, Yen Ling ^b,c   Loh, Shih Hurng ^b   Chen, Po Yuan ^e   Hong, Chuang Ye ^c   Chen, Jin Jer ^d   Cheng, Tzu Hurng ^e   Liu, Ju Chi ^c  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cardiac fibroblasts; Endothelin 1; Extracellular signal regulated kinase; Magnolol; Reactive oxygen species; U II

Indexed keywords

ACETYLCYSTEINE; ENDOTHELIN 1; MAGNOLOL; MITOGEN ACTIVATED PROTEIN KINASE; REACTIVE OXYGEN METABOLITE; UROTENSIN II;

ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG INHIBITION; FIBROBLAST; HEART MUSCLE CELL; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; SIGNAL TRANSDUCTION; TISSUE CULTURE;

ANIMALS; ANIMALS, NEWBORN; BIPHENYL COMPOUNDS; CELL PROLIFERATION; CELLS, CULTURED; FIBROBLASTS; GROWTH INHIBITORS; LIGNANS; MYOCARDIUM; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY; UROTENSINS;

EID: 67650739544     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05144.x     Document Type: Article

References (23)

1. Diez J. Mechanisms of cardiac fibrosis in hypertension. J. Clin. Hypertens. 2007 9 : 546 50.
2. Ames RS, Sarau HM, Chambers JK et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999 401 : 282 6.
3. Matsushita M, Shichiri M, Fukai N et al. Urotensin II is an autocrine/paracrine growth factor for the porcine renal epithelial cell line, LLCPK1. Endocrinology 2003 144 : 1825 31.
4. Bousette N, Giaid A. Urotensin-II and cardiovascular diseases. Curr. Hypertens. Rep. 2006 8 : 479 83.
5. Zhang YG, Li YG, Liu BG et al. Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. Acta Pharmacol. Sin. 2007 28 : 36 43.
6. Bousette N, Pottinger J, Ramli W et al. Urotensin-II receptor blockade with SB-611812 attenuates cardiac remodeling in experimental ischemic heart disease. Peptides 2006 27 : 2919 26.
7. Chen YL, Liu JC, Loh SH et al. Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts. Eur. J. Pharmacol. 2008 593 : 24 9.
8. Hong CY, Huang SS, Tsai SK. Magnolol reduces infarct size and suppresses ventricular arrhythmia in rats subjected to coronary ligation. Clin. Exp. Pharmacol. Physiol. 1996 23 : 660 4.
9. Lin MH, Chao HT, Hong CY. Magnolol protects human sperm motility against lipid peroxidation: A sperm head fixation method. Arch. Androl. 1995 34 : 151 6.
10. Pacher R, Stanek B, Hulsmann M et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J. Am. Coll. Cardiol. 1996 27 : 633 41.
11. Turner NA, O'Regan DJ, Ball SG, Porter KE. Endothelin-1 is an essential co-factor for beta2-adrenergic receptor-induced proliferation of human cardiac fibroblasts. FEBS Lett. 2004 576 : 156 60.
12. Ammarguellat F, Larouche I, Schiffrin EL. Myocardial fibrosis in DOCA-salt hypertensive rats: Effect of endothelin ET(A) receptor antagonism. Circulation 2001 103 : 319 24.
13. Harada M, Saito Y, Kuwahara K et al. Interaction of myocytes and nonmyocytes is necessary for mechanical stretch to induce ANP/BNP production in cardiocyte culture. J. Cardiovasc. Pharmacol. 1998 31 (Suppl. 1 S357 9.
14. Harada M, Itoh H, Nakagawa O et al. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: Evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 1997 96 : 3737 44.
15. Motte S, van Beneden R, Mottet J et al. Early activation of cardiac and renal endothelin systems in experimental heart failure. Am. J. Physiol. Heart Circ. Physiol. 2003 285 : H2482 91.
16. Papadopoulos P, Bousette N, Giaid A. Urotensin-II and cardiovascular remodeling. Peptides 2008 29 : 764 9.
17. Johns DG, Ao Z, Naselsky D et al. Urotensin-II-mediated cardiomyocyte hypertrophy: Effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch. Pharmacol. 2004 370 : 238 50.
18. Dai HY, Kang WQ, Wang X et al. The involvement of transforming growth factor-beta1 secretion in urotensin II-induced collagen synthesis in neonatal cardiac fibroblasts. Regul. Pept. 2007 140 : 88 93. (Pubitemid 46316790)
19. Djordjevic T, Be I, Aiba RS et al. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2005 25 : 519 25.
20. Ho JW, Jie M. Pharmacological activity of cardiovascular agents from herbal medicine. Cardiovasc. Hematol. Agents Med. Chem. 2007 5 : 273 7.
21. Lee YM, Hsiao G, Chen HR, Chen YC, Sheu JR, Yen MH. Magnolol reduces myocardial ischemia/reperfusion injury via neutrophil inhibition in rats. Eur. J. Pharmacol. 2001 422 : 159 67.
22. Kim HM, Bae SJ, Kim DW et al. Inhibitory role of magnolol on proliferative capacity and matrix metalloproteinase-9 expression in TNF-alpha-induced vascular smooth muscle cells. Int. Immunopharmacol. 2007 7 : 1083 91.
23. Zhang AY, Chen YF, Zhang DX et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am. J. Physiol. Renal Physiol. 2003 285 : F792 8.